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Abstract
The majority of HIV infected individuals fail to produce protective antibodies and have
diminished responses to immunization1–3. We report that even though there is an expansion of T
follicular helper (Tfh) cells in HIV infected individuals, these are unable to provide adequate B
cell help. A higher frequency of PD-L1+ germinal center (GC) B cells from lymph nodes of HIV
infected individuals suggested a potential role for PD-1/PD-L1 interaction in regulating Tfh cell
function. In fact, engagement of PD-1 on Tfh cells led to a reduction in cell proliferation,
activation, ICOS expression and IL-21 cytokine secretion. Importantly, blocking PD-1 signaling
enhanced HIV-specific immunoglobulin production in vitro. We further show that at least part of
this defect involves IL-21 as addition of this cytokine rescued antibody responses and plasma cell
generation. Our results suggest that deregulation of Tfh-mediated B cell help diminishes B cell
responses during HIV infection and may be related to PD-1 triggering on Tfh cells. These results
show, for the first time, a role for Tfh cell function in HIV pathogenesis and suggest that an
alteration in their function could have a significant impact on the outcome and control of HIV
infection, future infections and vaccinations.
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During HIV infection there is a profound deregulation in B-cell function4–6. However, little
is known about the underlying mechanisms that alter B cell responses and antibody
production at the site of their origin, the lymphoid tissues. The dynamic interplay between
Tfh cells and GC B cells is essential in establishing protective humoral immune responses.
Furthermore, the rare and broad neutralizing anti-HIV antibodies against different strains of
HIV are enriched with somatic hypermutations7–9, a property that is largely the result of Tfh
interaction with GC B cells. It has further been shown, in the LCMV mouse model, that
sustained Tfh function is required to control persistent viral infection10,11. Preserving and
enhancing Tfh function could therefore prove imperative in promoting efficient humoral
defenses against HIV and improving the outcome of vaccination in infected patients.
We studied lymph node mononuclear cells (LNMCs) from healthy controls and ART-naïve,
HIV-1-infected subjects (CD4 T-cell count > 350 per mm3 and plasma HIV RNA levels >
2000 copies ml−1) (Supplementary Table. 1). Initial characterization demonstrated a
significant increase (P = 0.0012) in the frequency of Tfh cells in HIV-infected LNs (Fig. 1a)
and more than 90% of these cells expressed Bcl-6, the master regulator for Tfh cells, and
PD-1, confirming their Tfh identity (Supplementary Fig. 1a–c)12. No significant differences
were observed in the naïve, central memory or effector memory CD4+ T cell compartments
(Fig. 1a) (Supplementary Fig. 2 for gating strategies). We also observed a significant
increase (P < 0.0003) in the frequency of GC B cells and a significant reduction (P < 0.02)
in the frequency of memory B cells in HIV-infected LNs (Fig. 1b). These results indicate
that in HIV-infected LNs there is an expansion of Tfh cells and GC B cells likely driven by
chronic infection and antigen accumulation within the follicular microenvironment13,14.
These results are in accordance with recently published reports in humans15 and
macaques16,17.
To investigate whether the function of Tfh cells is affected during HIV infection, we
generated an in vitro coculture system in which sorted Tfh and non-Tfh cells are placed in
coculture with sorted autologous GC-enriched B cells in the presence of staphylococcal
enterotoxin B (SEB). This coculture system allows for the quantification of Tfh-mediated B
cell help by measuring the accumulation of immunoglobulin in the culture supernatant and
the absolute numbers of live cells at different time points (Supplementary Fig. 3a, b). Using
this assay we found that cocultures from HIV+ LNs had a 92% reduction in the levels of IgG
when compared to cocultures from control LNs (Fig. 1c, d). This reduction was also
observed in cocultures from SIV+ macaques (Supplementary Fig. 4a). The absolute number
of live B cells and Tfh cells was also significantly (P < 0.01 and P < 0.02) reduced after 7 d
in coculture (Fig. 1e, f). A decrease in the levels of IL-10 was also observed in cocultures
from HIV+ subjects (Supplementary Fig. 5). We were unable, however, to quantify the
levels of IL-21 in the supernatants likely due to its rapid consumption. These results suggest
that in LNs from HIV+ individuals, Tfh cell function is altered and this affects B cell
survival and antibody production.
We next explored the phenotype of Tfh cells in HIV-infected and uninfected LNs. Tfh cells
from HIV+ and control LNs expressed similar levels of Bcl-6, ICOS, CD40L and PD-1 (Fig.
2a, b and Supplementary Fig. 6). Tfh cells sorted from infected and uninfected LNs secreted
similar levels of cytokines including IL-4, IL-10 and IL-21. In fact, we observed a tendency
towards higher IL-21 production in Tfh cells from HIV-infected individuals (Supplementary
Fig. 7). Thus, Tfh cells from both infected and uninfected LNs appear to be phenotypically
similar suggesting that the alteration in Tfh cell function observed in the cocultures could
arise from their interaction with B cells.
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Since HIV infection is known to affect intrinsic B cell function4,18,19, we investigated the
status of LN resident B cells. Naïve, GC and memory B cells from LNs of HIV+ subjects
expressed higher levels of CD95 than their counterparts from control LNs suggesting an
increased propensity to apoptosis (Supplementary Fig. 8a, b). We next examined the
capacity of B cells to survive without any T cell help and to produce immunoglobulin
following polyclonal stimulation with CpG-B20. We showed that GC-enriched B cells from
HIV+ LNs produced similar levels of IgG to those from control LNs (Supplementary Fig.
9a). The viability of these cells was reduced, but not significantly, in HIV infected LN
(Supplementary Fig. 9b). We also observed a tendency towards reduced levels of IL-6 from
GC-enriched B cells from HIV+ LNs (Supplementary Fig. 9c) which could impact IL-21
secretion from Tfh cells21.
Since Tfh cells express high levels of the negative regulator PD-1 we next investigated
whether expression of its ligands was increased in B cell subsets from HIV+ LNs. A
significantly (P = 0.015) higher frequency of GC B cells from HIV+ LNs expressed PD-L1
(Fig. 2c). This was specific for GC B cells as naïve, early memory and late memory B cells
showed a similar frequency of PD-L1 expression. We did not observe any differences in PD-
L2 expression (Fig. 2d). Importantly, staining of LN tissue sections from HIV+ subjects
showed an abundant expression of PD-L1 within the follicles (Fig. 2e). The levels of PD-L1
expression within the GC area were noticeably higher in LNs from HIV+ individuals and
this was also the case for LN samples from SIV-infected macaques. These results suggest
that the increased frequency of PD-L1+ GC B cells could be affecting Tfh cell function.
We next examined whether PD-1 triggering on Tfh cells could result in functional
alterations that could affect B cell help. Tfh cells from uninfected tonsils were sorted and
cultured in the presence of anti-CD3, anti-CD28 and PD-L1 coated beads (PD-L1 beads) to
trigger PD-1 in the context of T-cell receptor activation, or anti-CD3, anti-CD28 and isotype
control coated beads (control beads) or left unstimulated. When Tfh cells were cultured in
the presence of control beads there was a significant (P < 0.001) induction in Ki-67 and
CD38 expression suggesting an increased proliferative capacity. However, stimulation with
PD-L1 beads reduced the frequency of Ki-67+ and CD38+ Tfh cells (Fig. 3a). This was
translated into a decrease in the frequency and absolute number of live Tfh cells (Fig. 3b).
This reduction in Ki-67 expression was maintained after five days (Fig. 3c). Unexpectedly,
triggering PD-1 also inhibited ICOS expression (Fig. 3d) which could affect IL-4 and IL-21
cytokine secretion22. In fact, PD-1 triggering led to a 60% decrease in the levels of IL-21
(Fig. 3e) and a 78% and 95% decrease in the levels of IL-4 and IL-10 respectively
(Supplementary Fig. 10). These results suggest that PD-1 triggering on Tfh cells affects
multiple central aspects of Tfh cell biology including cytokine secretion.
If PD-1 triggering on Tfh cells from HIV+ LNs could affect IL-21 secretion, that is critical
for B cell survival and differentiation into plasma cells, then supplementation with IL-21
should restore and enhance antibody production. In fact, cocultures of Tfh cells from
infected LNs showed a significant restoration in IgG production when supplemented with
IL-21 to the levels observed in cocultures from control LNs (Fig. 4a, b). Addition of IL-21
increased the amount of IgG produced by B cells in the coculture and led to a dose-
dependent increase in CD27 MFI on B cells suggesting the accumulation of plasma cells
(Fig. 4c). IL-21 supplementation also led to an apparent increase in the absolute number of
live B cells (Fig. 4d) in accordance with the ability of IL-21 to promote B cell
differentiation, survival and proliferation in the context of B cell help23.
We next determined whether exogenous IL-21 could enhance HIV-specific Tfh responses.
Tfh cells and GC-enriched B cells were sorted and cultured with primed monocytes for
seven days in the presence or absence of IL-21. Addition of IL-21 enhanced antigen specific
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Tfh-mediated B cell responses (Fig. 4e). We also tested whether blocking PD-1 engagement
with its ligands could restore antibody production. For this, Tfh cells, B cells and primed
monocytes were cultured in the presence or absence of anti-PD-L1 and PD-L2 blocking
antibodies or isotype control. Blocking PD-L1 and PD-L2 increased IgG production by 78%
when compared to the isotype control group (Fig. 4f). As expected there was no increase in
the levels of IgG when the PD-1 pathway was blocked in cocultures from uninfected
subjects (Supplementary Fig. 11). Overall, these results highlight a potential role for PD-1
engagement and IL-21 in altering Tfh-mediated B cell help during HIV infection. They
further indicate that interfering with PD-1 triggering could enhance HIV-specific humoral
defenses that are compromised during HIV infection.
Even though Tfh cells from control and HIV+ LNs were phenotypically similar, the function
of these cells is altered in the presence of B cells. Interestingly, in a mismatch coculture
assay using Tfh and GC-enriched B cells before and after SIV infection (Supplementary Fig.
4b) we observed that only GC-enriched B cells from SIV+ macaques, which also express a
higher frequency of PD-L1 (Fig. 2e), affected Tfh-mediated B cell responses and
immunoglobulin production. These results reinforce the idea that the Tfh cells themselves
are not dysfunctional, but rather, their function is affected once they come into contact with
PD-L1 expressing B cells.
Here we propose a model in which HIV infection drives the expansion of both Tfh and GC
B cells, but the heightened levels of activation and antigen overload likely increases the
frequency of PD-L1+ GC B cells leading to excessive and persistent triggering of PD-1 on
Tfh cells affecting their capacity to provide B cell help. This effect combined with B cell
intrinsic defects, results in the inability to mount appropriate Tfh-mediated B cell responses.
Even though HIV infected subjects show hypergammaglobulinemia, this likely arises from
hyperactivated naïve B cells1. Similarly, an increase in SIV-specific antibodies has been
associated with the accumulation of Tfh cells17, but their level and function could be
suboptimal preventing the generation of efficient antibody responses (magnitude and
breadth). Alternatively, these SIV-specific antibodies could have been generated
independently of Tfh cells. It is important to note that in this study we were unable to
distinguish Tfh cells from T follicular regulatory (Tfr) cells which also express CXCR5 and
which could affect Tfh-mediated B cell responses24–27. It will be important to determine
their presence and function during HIV infection.
PD-L1 expression on B cells has been shown to negatively regulate Tfh cell expansion in
mice28. Here we show that PD-1 triggering affects Tfh cell function leading to reduced
ICOS expression which could affect downstream transcription factors like c-Maf29–31 and
subsequently IL-4 and IL-21 cytokine secretion thereby affecting B cell help
(Supplementary Fig. 12). It is known that the majority of HIV infected individuals have a
delay in the generation and an absence of broadly neutralizing HIV-specific
antibodies4,32,33. To what extent the alteration in Tfh cell function has an impact on the
timing of production and on the quality of neutralizing antibodies remains to be determined.
The signals leading to increased PD-L1 expression on GC B cells are unclear, but are likely
the result of increased levels of interferons that can upregulate PD-L1 expression34.
Treatment of mice with blocking anti-PD-L1 or PD-1 antibodies has been shown to enhance
Tfh cell expansion and function and increase the number of GC B cells, plasmablasts and
antigen specific antibody responses28,35. Similarly, PD-1 blockade in macaques improved
humoral responses and increased SIV specific antibody responses36. Our work, together
with these studies, suggests a critical role for the PD-1 pathway in regulating Tfh cell
function. Because of persistent PD-L1 expression on GC B cells, Tfh cells in HIV infected
subjects may lose their ability to properly generate de novo humoral responses to new
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infections and their ability to respond to vaccinations. Consistent with this are the reduced
levels in antibody responses to Hepatitis B, measles, mumps and rubella vaccines in HIV+
subjects2,37,38. Overall, our results suggest that for effective vaccination of HIV-infected
individuals, the proper function of Tfh cells needs to be considered.
Online Methods
Study subjects
All procedures were approved by the Institutional Review Boards at the relevant institutions,
and all participants gave written informed consent before all procedures. Whole pelvic
lymph nodes were obtained from adult women not known to be HIV-1 infected who were
undergoing medically indicated surgery at University Hospitals of Cleveland. Their average
age was 53 ± 14 years. ART-naïve HIV-1-infected individuals were recruited at the Drexel
University College of Medicine (Philadelphia, PA). Average age of these subjects was 43 ±
13 years. All were naïve to ARV therapy and had HIV-1 RNA levels in their plasma ≥ 2000
copies ml−1. The CD4+ T cell count in these subjects was 514 ± 120 cells ml−1. Lymph
nodes were excised from the inguinal region under local anesthesia as described
previously39. Surgeries were performed in the morning and the excised nodes were then
placed in RPMI medium and shipped to Case Western Reserve University at 4 °C via same
day air along with matching peripheral blood. The time between biopsy and subsequent
specimen processing was no more than 7 hours.
We analyzed 2 Rhesus macaques longitudinally pre-infection and during chronic infection.
Rhesus macaques (Indian origin Macaca mulatta; RMs) were seronegative for simian
retrovirus type D, simian T-cell lymphotropic virus, and SIV at study initiation and did not
express protective MHC-I alleles (MamuB*08, MamuB*17). RMs were infected with either
SIVmac239 or SIVsmE660. Peripheral lymph node biopsies were obtained before infection
and during chronic infection. Animals were housed and cared in accordance with the
American Association for Accreditation of Laboratory Animal Care standards in AAALAC
accredited facilities, and all animal procedures were performed according to protocols
approved by the Institutional Animal Care and Use Committees of the National Cancer
Institute, National Institutes of Health.
Processing of lymph nodes
Upon receipt of tissue, LNs were washed once in ice cold PBS. After careful removal of
surrounding fatty tissue, LNs were cut into 1 mm × 1 mm tissue blocks and digested with
collagenase IV (5 mg ml−1 in RPMI) (GIBCO) supplemented with 0.5% fatty acid-free BSA
(Sigma-Aldrich) and 200 μg ml−1 DNAse I (Roche). Collagenase-digested tissues were then
mechanically digested with a motorized pestle, and the liberated cell suspensions were
placed through a 40-micron nylon mesh and washed once in RPMI 1640. These LNMCs
were then cryopreserved and used for the different assays.
Processing of tonsils
Tonsils were dissected into small fragments and the pieces were subsequently minced by
mechanical disruption between two fully frosted glass slides in complete RPMI 1640 media.
Cells were then collected and filtered through a 70 μm nylon membrane mesh and washed in
complete media. TMNCs were then separated by Ficoll-density centrifugation. TMNCs
were removed and washed twice in complete RPMI 1640 media. Cells were then
cryopreserved for subsequent use.
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Immunohistochemistry for mouse anti-PDL1 (clone 339.7G11) (kind gift from Gordon
Freeman) and rabbit monoclonal anti-CD23 (clone SP23; Lab Vision, Thermo Fisher
Scientific, Inc) was performed using a biotin-free polymer approach (Mouse or Rabbit
Polink-2, Golden Bridge International, Inc.) on 5 μm tissue sections mounted on glass slides,
which were dewaxed and rehydrated with double-distilled H2O. Antigen retrieval was
performed by heating sections in 0.01% citraconic anhydride in a pressure cooker set at 125
°C for 30 s. Slides were rinsed in ddH2O, blocked in 0.25% casein and incubated with either
diluted mouse anti-PDL1 (1:100; 7 μg mL−1) or rabbit anti-CD23 (1:100) in diluent (1x TBS
with 0.05% Tween-20 and 0.25% casein) overnight at 4 °C. Tissue sections were rinsed in
wash buffer (1x TBS containing 0.05% Tween-20) for 10 min followed by an endogenous
peroxidase blocking step using 1.5% (v/v) H2O2 in TBS (pH 7.4) for 10 min and place in
wash buffer. Slides were incubated with Mouse or Rabbit Polink-2 HRP polymer staining
system (Golden Bridge International, Inc) according to manufacturer’s recommendations
(30 min at room temperature) followed by rinsing in wash buffer. Tissue sections were
developed with Impact(™) 3,3′-diaminobenzidine (Vector Laboratories), counterstained with
Hematoxylin and mounted in Permount (Fisher Scientific). Representative images were
acquired using a Nikon 80i bright field microscope. Scale bar, 50 μm.
Antibodies
The following fluorochrome-conjugated antibodies were used: anti-human CD3 (clone
UCHT1, 1:200), anti-human CD4 (clone RPA-T4, 1:200), anti-human CD19 (clone HIB19,
1:100), anti-human CD27 (clone O323, 1:100), anti-human CD38 (clone HIT2, 1:100), anti-
human CD95 (clone DX2, 1:100), anti-human ICOS (clone C398.4A, 1:100), anti-human
CD40L (clone 24–31, 1:10), anti-human PD-1 (clone EH12.2H7, 1:100) (all from
BioLegend). Additional antibodies were: anti-human CXCR5 (clone RF8 B2, 1:200), anti-
human Bcl-6 (clone K112-91, 1:20), anti-human IgD (clone IA6-2, 1:50), anti-human Ki-67
(MOPC-21, 1:10), anti-human PD-L1 (clone MIH1, 1:20), anti-human PD-L2 (clone
MIH18, 1:10) from BD Biosciences and anti-human CD45RA (clone 2H4LDH11LDB9,
1:200) from Beckman Coulter. LIVE/DEAD® Fixable Dead Cell Stain from Invitrogen was
used to gate on live cells as well as Annexin V from BD Biosciences.
For the generation of beads the CELLection™ Pan Mouse IgG kit was used (Life
Technologies 11531D). To coat the beads purified mouse anti-human CD3 (clone UCHT1)
and anti-human CD28 (clone CD28.2) from BD Biosciences was used. For isotype control
to chimeric murine IgG2a human PD-L1 (kind gift from Gordon Freeman), mouse IgG2a
isotype control (M5409) from Sigma-Aldrich was used.
Cell sorting
For isolation of T cell and B cell subsets, LMNCs were thawed and stained with ViViD,
CD3 A700, CD4 APC H7, CD45RA ECD, CXCR5 AlexaFluor647, CD19 PE Cy7 and
CD27 FITC- specific antibodies at to 4 °C for 20 min before sorting to obtain highly
enriched Tfh cells ViViD−CD3+CD4+CD45RA−CXCR5hi, non-Tfh cells
ViViD−CD3+CD4+CD45RA−CXCR5−, ViViD−CD3+CD4+CD45RA+ and GC-enriched B
cells ViViD−CD3−CD19+CD27+. Cells were sorted using a BD FACSAria™ II (BD
Biosciences).
Coculture assay
Sorted (2 × 104) GC-enriched B cells were cocultured with Tfh
(Vivid−CD3+CD4+CD45RA−CXCR5hi) or non-Tfh (CD3+CD4+CD45RA−CXCR5−or
CD3+CD4+CD45RA+) cells at a 1:1 ratio in the presence of 100 ng ml−1 of staphylococcal
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enterotoxin B (SEB) in 96-well V-bottom plates. Supernatants and cells were harvested on
day 7 to analyze by ELISA the total levels of IgG and cell viability by flow cytometry and
trypan blue exclusion counting to obtain absolute numbers. For cocultures with antigen
specific stimulation sorted Tfh cells were cultured with GC-enriched B cells and primed
CD14+ monocytes (Gag and Env peptide pools) at a 1:1:1 ratio (3 × 104 cells each) for 7
days in 96-well V-bottom plates. The monocytes were obtained by negative selection using
magnetic beads (StemCell Technologies) from autologous PBMCs. The HIV-1 consensus B
Gag and Env 15 amino acid peptide pools with 11 amino acid overlaps were obtained
through the NIH AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH (Cat# 9480 and 8117). Isolated monocytes were allowed to rest for 1 h at 37 °C
and primed for 2 h at 37 °C followed by addition to the cocultures. For all coculture
experiments a titrated amount (to prevent virus replication without affecting cell viability) of
AZT (180nM) was added at the onset of the experiment. For the PD-L1 and PD-L2 blocking
experiments 20 μg ml−1 of anti-human PD-L1 and PD-L2 blocking antibodies or isotype
control (eBioscience) were added at the onset of the coculture for 20 min at 37 °C prior to
the addition of Tfh cells.
PD-1 triggering with beads
Purified mouse anti-human CD3, mouse anti-human CD28 (BD Biosciences), chimeric
murine IgG2a human PD-L1 (kind gift from Gordon Freeman) or isotype control (murine
IgG2a) (Sigma-Aldrich) were covalently attached to CELLection™ Pan Mouse IgG
Dynabeads® (Invitrogen). For 2 × 107 beads a total concentration of 140 ng of anti-human
CD3, 33 ng of anti-human CD28 and 500 ng of PD-L1 ligand (or isotype control) was used.
A total of 2 × 105 sorted Tfh cells (CXCR5hi) were cultured in the presence of beads (PD-
L1, control IgG2a or left unstimulated) for 3 days. A total ratio of 2 beads cell−1 was used.
Cells were then collected for analysis by flow cytometry and the culture supernatants used
for detection of cytokines by ELISA or CBA.
ELISA
96-well Immulon 2HB plates (Thermo Scientific) were coated overnight at 4 °C with
monoclonal anti-human IgG (Mabtech, clone MT91/145) antibodies at a concentration of 1
μg ml−1 in carbonate bi-carbonate buffer. Plates were washed 5 times with PBS + 0.05%
tween-20 in the following day. Plates were subsequently blocked for 1 h with PBS + 10%
FBS at RT. Plates were then washed and the culture supernatants added at different dilutions
for 1 h at RT. After washing the plates these were incubated with 1μg ml−1 of anti-human
IgG-biotin (Mabtech, clone MT78/145) for 1 h at RT. The plates were then washed and
incubated with streptavidin-HRP (Mabtech) for 45 min at RT. Plates were subsequently
washed and 100 μl of TMB substrate (Sigma-Aldrich) added until appearance of color. The
enzymatic reaction was stopped by adding 50 μl of 1M H3PO4. The OD (450 nM) was then
measured using a SpectraMax plus 384-plate reader (Molecular Devices).
Luminex and CBA
Sorted CD4 T-cell populations were stimulated with phorbol myristate acetate (PMA; 100
ng mL−1; Sigma-aldrich, USA) and Ionomycin (1 μg mL−1) (Sigma-Aldrich) in complete
RPMI (18 h, 37 °C, 5% CO2). Supernatants were then collected and analyzed for the
presence of cytokines by Luminex (Millipore) following the manufacturer’s protocol. For
Cytometric Bead Assay (CBA) analysis, supernatants from the cocultures were collected
and prepared according to the manufacturer’s protocol (BD Biosciences).
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All statistical analyses were performed using the non-parametric Mann-Whitney test,
assuming independent samples. This test uses the rank of the data rather than their raw
values to calculate the statistical significance and is an alternative to the t-test, when the
assumption of normality is not satisfied or could not be tested in the case of small sample
sizes. When comparing supplementation of cocultures with IL-21 or PD-1 triggering on Tfh
cells by using the bead system the paired Student’s t-test assay was used as these samples
were paired to their control groups. When comparing the % of IgG with respect to HIV−
LNs the Wilcoxon signed rank column test was used. In this study, P-values of less than
0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Tfh cells from HIV-infected subjects are unable to provide appropriate B cell help. (a)
Frequency of T cell and B cell subsets in LNs from HIV− and HIV+ subjects. T cell subsets
were defined as: naïve (CD3+CD4+CD45RA+CD27+), central memory
(CD3+CD4+CD45RA−CD27+), effector cells (CD3+CD4+CD45RA−CD27−) and Tfh cells
(CD3+CD4+CD45RA−CXCR5hi). (b) B cell subsets were defined as: naïve
(CD3−CD19+CD38−IgD+), GC (CD3−CD19+CD38++IgD−) and total memory B cells
(CD3−CD19+CD38+/−IgD−). For T cell subsets (HIV− n=9; HIV+ n=9) for Tfh cell subset
(HIV−n=10; HIV+ n=13) for B cell subsets (HIV− n=11; HIV+ n=12). (c) IgG production
(ng ml−1) in cocultures from LNMCs of HIV− and HIV+ subjects after 7 d (HIV− n=6; HIV+
n=6) as measured by ELISA. (d) Percent difference in the levels of secreted IgG from
cocultures of Tfh cells and GC-enriched B cells from HIV+ LNMCs when compared to
uninfected controls (HIV− n=6; HIV+ n=6). (e) Absolute number of B cells in coculture with
Tfh and non-Tfh cells (HIV− n=6; HIV+ n=6) (f) Absolute number of Tfh cells after 7 d
(HIV− n=6; HIV+ n=6) in coculture.
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Ex-vivo characterization of Tfh cells and B cells in LNs from HIV-infected and uninfected
individuals. (a) Enrichment of Tfh cells in the CXCR5hi population of both HIV− and HIV+
LNMCs as determined by Bcl-6, ICOS and PD-1 staining. (b) Expression levels of PD-1 on
Tfh cells from HIV− and HIV+ LNMCs as measured by mean fluorescence intensity (MFI).
(c) Frequency of PD-L1 expression on B cell subsets from infected and uninfected LNMCs.
Subsets were defined as naïve (CD3−CD19+CD38−IgD+), GC (CD3−CD19+CD38hiIgD−),
early memory (CD3−CD19+CD38+IgD−) and late memory (CD3−CD19+CD38−IgD−)
(HIV− n=6; HIV+ n=6). (d) Frequency of PD-L2 expression on B cell subsets (HIV− n=5;
HIV+ n=5). (e) Representative images for PD-L1 staining on LN sections from HIV-
uninfected (n=6) and infected (n=5) subjects as well as SIV-uninfected (n=4) and infected
(n=2) macaques. Scale bar, 50 μm.
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Triggering PD-1 on Tfh cells leads to a decrease in cell proliferation, activation and cytokine
secretion. Tfh cells from tonsil mononuclear cells (TMNCs) of uninfected individuals were
cultured for 3 d in the presence of anti-CD3, anti-CD28 and isotype coated beads (Stim),
anti-CD3, anti-CD28 and PD-L1 coated beads (Stim + PD-L1) or left unstimulated
(Unstim). (a) Frequency of Ki-67 and CD38 expression on Bcl-6+ Tfh cells. The dot plots
depict the percent of Ki-67+ and CD38+ Tfh cells after stimulation with the beads (n=10).
(b) Effect of PD-1 triggering on the frequency and absolute number of live Tfh cells (n=10)
(c) Percent of Ki-67+ Bcl-6+ Tfh cells at different time points after stimulation with the
beads (n=3; *P < 0.01; **P < 0.001 between control and PD-L1 beads). (d) Effect of PD-1
triggering on the absolute number of ICOS+ Tfh cells and ICOS MFI (n=5). Results are
representative of two independent experiments (e) Effect of PD-1 triggering on IL-21
secretion as measured by ELISA on day 3 (n=4).
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Supplementation with IL-21 restores IgG production in co-cultures from HIV-infected LNs.
(a) Representative graph depicting IgG levels in co-cultures of GC-enriched B cells with
CXCR5hi, CXCR5− or CD45RA+ T cell subsets in the presence of SEB with or without
recombinant human IL-21 (10 ng ml−1) after 7 d. (b) Increase in IgG production and CD27
MFI on B cells when cocultures of Tfh and GC-enriched B cells from HIV+ LNMCs are
supplemented with IL-21 (n=5). (c) Dose dependent effect of IL-21 on IgG production and
CD27 MFI on B cells (n=4). (d) Dose dependent effect of IL-21 supplementation on the
absolute number of B cells and IgG production in co-cultures of Tfh and GC-enriched B
cells from HIV+ LNMCs (n=4) after 7 d. (e) Effect of IL-21 supplementation on total IgG
levels following antigen specific stimulation by culturing Tfh cells and GC-enriched B cells
in the presence of primed monocytes after 7 d. (n=2). (f) Effect of PD-L1/L2 blocking on
IgG production in cocultures of Tfh cells and GC-enriched B cells in the presence of primed
monocytes after 7 d (n=2).
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